Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENSC vs CELU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENSC Captures Overall Composite Edge (53.4 HOLD vs 42.9 HOLD), While CELU Leads 4–1 on Growth & Valuation Pillars

ENSC Overall Winner 6-Pillar Tally: ENSC 1 – 4 CELU (1 Tie) Matrix Metrics: ENSC 6 – 3 CELU

As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (53.4/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–3 (led by Valuation Multiples), while CELU wins 4–1 across the 6-pillar growth and valuation breakdown. ENSC trades at $0.36 (0.8x Forward P/E, -281.3% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin).

  • Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. CELU 42.9/100 HOLD) and 0.98β · 79% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENSC vs CELU
ENSC NASDAQ Head-to-Head Winner
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (ENSC 1 – 4 CELU)

Columns: Metric · ENSC · CELU
1. Valuation Multiples ENSC
Forward P/E 0.8x N/M
Trailing P/E 0.8x N/M
PEG Ratio N/M N/M
EV / Revenue 1.4x 2.7x
2. Growth & Scale CELU
Revenue Growth (YoY) -15.1% -5.3%
Earnings Growth (YoY) +0.0% -61.3%
TTM Revenue (USD) $4.5M $19M
Market Cap $7.0M $15.2M
3. Profitability & Quality CELU
Gross Margin N/A 19.2%
Operating Margin -281.3% -254.0%
Net Profit Margin -280.5% -245.7%
Return on Equity (ROE) -1295.1% -6367.2%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) -$9.7M -$8.9M
Cash Flow Margin N/A -47.8%
Net Cash / Leverage -$499,633 Net Debt $35M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CELU
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 116.6% (50th %ile)
Put/Call OI Skew N/A 3.60x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENSC (6) vs CELU (3)
Institutional Metric ENSC CELU Criterion Row Edge
Market Capitalization
Scale
$7.0M $15.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
0.8x N/M Lower Multiple ENSC
Forward P/E Ratio
Valuation
0.8x N/M Lower Multiple ENSC
Revenue Growth (YoY)
Growth
-15.1% -5.3% Higher Growth CELU
Operating Margin (TTM)
Profitability
-281.3% -254.0% Higher Margin CELU
Net Profit Margin
Profitability
-280.5% -245.7% Higher Margin CELU
Return on Equity (ROE)
Capital Efficiency
-1295.1% -6367.2% Higher ROE ENSC
52-Week Range Position
Momentum
8% ($0–$2) 2% ($0–$3) Stronger Trend ENSC
Beta / 30D Volatility
Risk Regime
0.98β · 79% Vol 2.01β · 135% Vol Lower Realized Risk ENSC
Unified Institutional Score
Composite Signal
53.4 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
$4.5M $19M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 19.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.7M (-$499,633 Net Debt) -$8.9M ($35M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENSC +26.35 pp
ENSC: -29.55% · CELU: -55.9%
3M Horizon ENSC +39.96 pp
ENSC: -0.28% · CELU: -40.24%
6M Horizon ENSC +59.78 pp
ENSC: +12.99% · CELU: -46.79%
1Y Horizon CELU +7.73 pp
ENSC: -80.33% · CELU: -72.6%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENSC Revenue CELU Revenue ENSC Op. Margin CELU Op. Margin Margin Leader
FY2020 $0M $10M -41.0% -1064.0% ENSC
FY2021 $0M $20M -562.7% -511.2% CELU
FY2022 $0M $20M -959.9% -142.4% CELU
FY2023 $0M $20M -480.5% -844.4% ENSC
FY2024 $10M $50M -129.2% -70.7% CELU
FY2025 $10M $30M -202.1% -230.9% ENSC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENSC vs CELU Key Questions & Quantitative Answers

As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (53.4/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–3 (led by Valuation Multiples), while CELU wins 4–1 across the 6-pillar growth and valuation breakdown. ENSC trades at $0.36 (0.8x Forward P/E, -281.3% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin). Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. CELU 42.9/100 HOLD) and 0.98β · 79% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CELU leads the Growth & Scale pillar: ENSC posts -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENSC cumulative revenue shifted +0.0% while CELU shifted +200.0%. In operating R&D and SG&A reinvestment, ENSC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.

ENSC screens cheaper on headline valuation multiples. ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENSC (-1295.1% ROE) versus CELU (-6367.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.